Skip to main content
Premium Trial:

Request an Annual Quote

Peakadilly Changes Name to Pronota in Effort to Shore Up Biomarker Identity

This update corrects the spelling of the new company. It is Pronota, not Pronata.
 
NEW YORK (GenomeWeb News) — Belgian company Peakadilly has changed its name to Pronota to reflect its emphasis on protein biomarker discovery, the firm said today.
 
The company also said that a recent €8.5 million ($10.97 million) financing round has enabled it to expand its staff, equipment, and facilities, which it will use to position itself more squarely in the protein biomarker market.
 
Pronota said its signature biomarker technology, the MASStermind, is used to analyze proteomes from samples such as blood. It also plans to use the technology to develop new diagnostic disease screens and therapeutics.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.